GeneQuantum

Focus: GeneQuantum is an early-stage biotech company focused on antibody-drug conjugate (ADC) development, headquartered in Suzhou, China. Founded in 2020 and currently at Series A stage, the company is pre-revenue with no disclosed pipeline programs or approved products.

Oncology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About GeneQuantum

AI assessmentNot Hiring

No open roles listed right now. Follow GeneQuantum to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GQ1005

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

Phase 1

Clinical Trials (1)

NCT06154343A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Phase 1

Help build intelligence for GeneQuantum

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a company at the inflection point where Series A funding enables transition from platform to clinical programs in the high-value ADC space
Access to emerging Chinese biotech ecosystem with potential for rapid scaling and international expansion opportunity
Ground-floor opportunity to shape organizational culture, processes, and scientific direction in a newly founded company

Watch Out For

Zero clinical programs disclosed and no product revenue creates execution risk; company must validate ADC platform and advance to IND stage
Series A stage means limited cash runway visibility and typical 18-24 month pressure to raise Series B or demonstrate clinical proof-of-concept
No active job openings currently posted suggests either early hiring phase or reduced near-term headcount plans

Generated by Claude from GeneQuantum's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GQ1001

HER2-positive Breast Cancer

Phase 1

Clinical Trials (1)

NCT04450732Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Phase 1

GQ1001+pyrotinib

Advanced/ Metastatic Her-2 Positive Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT05575804GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Phase 1/2

Dose Escalation

Advanced Malignant Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT06464055A Study of GQ1010 in Subjects With Advanced Solid Tumors

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline